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Abstract 
Background 
The benign reputation of Plasmodium vivax is at odds with the burden and severity of the 
disease. This reputation, combined with restricted in vitro techniques, has slowed efforts to 
gain an understanding of the parasite biology and interaction with its human host. 
Methods 
A simulation model of the within-host dynamics of P. vivax infection is described, 
incorporating distinctive characteristics of the parasite such as the preferential invasion of 
reticulocytes and hypnozoite production. The developed model is fitted using digitized time-
series’ from historic neurosyphilis studies, and subsequently validated against summary 
statistics from a larger study of the same population. The Chesson relapse pattern was used to 
demonstrate the impact of released hypnozoites. 
Results 
The typical pattern for dynamics of the parasite population is a rapid exponential increase in 
the first 10 days, followed by a gradual decline. Gametocyte counts follow a similar trend, 
but are approximately two orders of magnitude lower. The model predicts that, on average, 
an infected naïve host in the absence of treatment becomes infectious 7.9 days post patency 
and is infectious for a mean of 34.4 days. In the absence of treatment, the effect of hypnozoite 
release was not apparent as newly released parasites were obscured by the existing infection. 
Conclusions 
The results from the model provides useful insights into the dynamics of P. vivax infection in 
human hosts, in particular the timing of host infectiousness and the role of the hypnozoite in 
perpetuating infection. 
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Background 
Historically, the high profile and lethal reputation of Plasmodium falciparum has meant that 
the bulk of malaria research and management has focused on this parasite; comparatively, the 
importance of Plasmodium vivax (and other species of human malaria) as a human pathogen 
has been neglected [1,2]. Yet despite a preconception that P. vivax is a benign infection, at 
least in comparison with P. falciparum, vivax malaria is a significant burden to nearly 40% of 
the world’s population, with estimates of between 132 and 391 million cases per year [2]; the 
greatest burden (52%) observed is in South and East Asia. Multiple reports have linked 
infection with P. vivax to patient death, often as a result of fatal complications and 
particularly in pregnant women and young children [3,4]. 
As the preconception of P. vivax as a benign disease agent is challenged, key questions 
remain regarding the basic ecology and dynamics of P. vivax infection [2]. 
The capacity of researchers to address these questions has been hampered by ongoing 
difficulties in producing an ex vitro culture system. Such a system was developed for P. 
falciparum in the 1970s [5] and drove subsequent research which provided a wealth of 
information on aspects of the parasite and infection [6]. With limited opportunities to 
investigate the dynamics of the parasite in the laboratory, modelling provides a useful 
alternative to explore aspects of P. vivax infection. 
This manuscript describes the development of a stochastic simulation model of the within-
host dynamics of a P. vivax infection in a naïve host, enabling elucidation of a number of 
significant questions regarding the interaction between host and parasite. It is intended that 
the development of this within-host model will subsequently have utility as the basis for a 
between-host model which incorporates multiple hosts and vectors. As P. falciparum is far 
better studied than P. vivax, the dynamics of this parasite is used as the basis for the model. 
However, it is important to recognize that there are several significant features that 
differentiate P. vivax from P. falciparum. These are detailed below. 
Preferential red blood cell invasion 
Plasmodium falciparum, while showing a weak preference for younger red blood cells 
(RBCs), is generally assumed to be capable of invading all RBC age classes, whilst P. vivax 
shows a strong preference for the youngest RBCs, reticulocytes [7,8]. It has been 
hypothesized that preferential invasion may play a key role in regulating the abundance of 
parasites in vivax malaria; increased competition between merozoites for a limited population 
of susceptible RBCs can slow the growth of an infection, ensuring that the host remains alive 
sufficiently long to maximize the chances of subsequent generations reinfecting a feeding 
mosquito [9]. Certainly the less discriminant P. falciparum is the human malaria species 
predominantly responsible for cases of severe disease and mortalities, while the other human 
Plasmodium species, which are more discerning in the RBCs they invade, are considered to 
be more benign disease agents [10]. 
Pyrogenic thresholds 
Fever is the most common clinical manifestation of malaria infection, and is a primary 
mechanism by which the host immune system can control infection, with increased body 
temperatures associated with parasite death. Higher fevers generally lead to greater parasite 
mortality. Fever is triggered by the rupture of mature schizont stage parasites and associated 
RBC lysis, with the pyrogenic threshold representing the density of parasites required to 
stimulate a febrile response to infection. Vivax malaria is generally accepted to have a lower 
pyrogenic threshold than falciparum malaria [2,11], thus fewer P. vivax parasites are required 
to trigger a fever in the host. 
Production of gametocytes 
During the erythrocytic stage of parasite development in humans, a fraction of parasites 
commit to a sexual development pathway. Different cells will produce male and female 
gametocytes, which can then be transmitted to a mosquito during a blood meal. Plasmodium 
vivax gametocytes vary from their P. falciparum equivalents by their presence in the blood at 
detectable levels during the primary attack of the disease whereas P. falciparum gametocytes 
cannot usually be seen on microscopy until some 9–12 days post infection [12]. It is unclear 
whether this difference is due to P. falciparum gametocytes sequestering in the bone marrow, 
or a longer gametocyte development time. The survival time of P. vivax gametocytes also 
appears to be significantly shorter than that of P. falciparum gametocytes [12]. 
Antigenic variation 
Approximately 12–14 hours after invasion, RBCs parasitized by P. falciparum express a 
strain-specific variant surface antigen (P. falciparum erythrocyte membrane protein 1 
PfEMP1), which mediates agglutination and adhesion of infected erythrocytes to the vascular 
endothelium and results in parasitized RBCs sequestering in the deep tissues, protected from 
splenic destruction [13,14]. PfEMP1 is encoded by a highly diverse family of genes, known 
as var genes, enabling rapid switching of presented antigens to evade the host immune 
response. While PfEMP1 and var gene switching have been the focus of intense study in P. 
falciparum, no clinically relevant equivalent has been identified in P. vivax [15]. 
Hypnozoites 
Hypnozoites, an exo-erythrocytic parasite life cycle stage derived from the initial inoculum of 
sporozoites, are characteristic of P. vivax, but not P. falciparum [16,17]. The hypnozoite 
stage is believed to provide a mechanism for the parasite to survive in environments where 
the presence of the mosquito vector is intermittent (e.g. in Finland or the Korean Peninsula, 
where mosquitoes overwinter during the winter months [18,19]). It is generally assumed that 
the duration of this dormant stage is genetically determined, but it has also been hypothesized 
that mosquito bites, or a host immune response triggered by other infections may ‘alert’ the 
hypnozoite to the presence of the vector [20]. 
Methods 
The basis of this work is a previously reported simulation model of preferential invasion of 
Plasmodia merozoites [9]. In brief, the probability of merozoites successfully invading a new 
host red blood cell was assumed to be a function of the relative abundance of RBCs (anaemic 
status of the host or how likely is it that a free merozoite will encounter an RBC) and the 
relative abundance of susceptible RBC age classes (having encountered an RBC, how likely 
is it that the RBC is of a susceptible age class). As an infection progresses, the probability of 
a free merozoite encountering a susceptible RBC is expected to fall. Such a fall reduces the 
probability of a successful merozoite invasion. As it is widely recognized that P. vivax 
preferentially invades reticulocytes, merozoite invasion was restricted to 1 and 2 day old 
RBCs. 
Mathematically, the number of merozoites which successfully invade RBCs is determined by 
drawing from the Binomial distribution ܤ൫੄੣੓੘ਖ਼੪੟ਫ਼੤੣ਖ਼ ൈ ੝੝ੑ੨, ੠ਖ਼൯ , where ௦ܰ௖௛௜௭௢௡௧௦೔  is the 
number of schizont stage parasites rupturing on day i and releasing merozoites, mmax is the 
maximum potential number of merozoites released per schizont, and pi is the probability of 
successful invasion on day i: 
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  is representative of relative RBC density (the degree of anaemia in the host) 
and 
ேೞೠೞ೎೔
ேೞೠೞ೎೚
  the proportion of susceptible RBCs available in the host on day i relative to day 0, 
while ci is a time-dependent clonal immunity function and 0.7 a scaling factor providing an 
adjustment from the biological maximum number of merozoites released (mmax), to the actual 
mean number of merozoites which usually develop and invade a new RBC in naïve hosts. It 
is assumed that ௧ܰ௢௧௔௟೚  is 2.5 × 10
13 and that ௦ܰ௨௦௖೚  is approximately 4.17 × 10
11 ( ௦ܰ௨௦௖೚  is 
approximately equal to ௧ܰ௢௧௔௟೚  / 60, but the exact value is dependent on the stochastic 
distribution of RBCs to the various age classes). The dynamics of the RBC (ie ௧ܰ௢௧௔௟೔  and 
௦ܰ௨௦௖೔ ) are as previously reported [9]. The immunity function is calculated as follows: 
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భబ , where β is drawn from a gamma distribution fitted during the 
modelling process. The only change to this model from the previous study [9] was that the 
duration over which clonal immunity develops was halved, based on declines in parasitaemia 
over time from published patient records [21]. It is assumed mmax is equal to 18 [8], resulting 
in an average of 12.72 released merozoites per replication cycle (Q1 = 11, Q3 = 14) at the start 
of an infection (i = 0). 
If the number of successful merozoites exceeds the number of available susceptible RBCs, 
the excess are removed from the system. 
To develop the model of within-host dynamics this base model was augmented to incorporate 
the effects of fever, the production of gametocytes and the release of dormant hypnozoite 
stages of the parasite. These additions were created as separate modules. In the absence of an 
identifiable mechanism of clinically relevant antigenic variation, it is assumed that the clonal 
immunity described above is the only specific host immune response that develops during 
infection. The model uses a 24 hour (1 day) time step and the duration of the erythrocytic 
cycle in P. vivax was assumed to be 48 hours; variability in the duration of the erythrocytic 
cycle and differences in the duration of each stage of the erythrocytic lifecycle [22] were not 
considered. 
Fever 
Representation of the fever response is largely derived from the work of Gatton and Cheng 
on P. falciparum [23], with some changes to account for known differences with P. vivax. 
Pyrogenic threshold figures for P. vivax have been reported in a number of prior studies; 310 
parasites/μL in southern Papua, Indonesia [24], 500 parasites/μL in analyses of children in 
Papua New Guinea [25], and 181 parasites/μL in Thailand [26]. For the current model, a 
pyrogenic threshold of 300 ± 200 parasites/μL is adopted. This value is considerably lower 
than the comparative value of 1,644 - 2,500 parasites/μL for P. falciparum [11,27]. Since 
information on the dynamics of the threshold during an infection is missing for P. vivax, it is 
assumed this threshold is not reached for a period of 7 days, and introduce a log-linear 
increase over these first seven days, following work by Gatton and Cheng on the pyrogenic 
threshold of P. falciparum [27]. 
When parasitaemia exceeds the pyrogenic threshold, a fever response is triggered. The 
strength of this response (fi) is equal to the number of additional parasites exceeding the 
threshold, as a proportion of the threshold, multiplied by a stochastic variable representative 
of the ‘strength’ of the fever response (gi): 
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Where ௣ܰ௔௥௔೔  is the number of parasites on day i and ௧ܰ௛௥௘௦௛௢௟ௗ೔  is the fever threshold as 
previously defined. gi is modelled using a gamma distribution, fitted during the modelling 
process. fi is limited to a minimum value of 0, and a maximum value of 10. The proportion of 
parasites surviving fever is assumed equivalent to exp-αf. Different parasite life cycle stages 
exhibit different susceptibilities to fever; the α term is used to incorporate this into the model. 
Following a review of the relevant literature [28,29], the model allows fever to impact on 
parasite survival such that late stage parasites are more susceptible to fever than early stage 
parasites (remembering that fever is most contemporaneous with early ring stage parasites, 
occurring shortly after schizont rupture), while gametocytes are considered less susceptible 
than ring stage parasites. Within the gametocyte sub-population, late stage gametocytes are 
considered more susceptible to fever than early stage gametocytes. Thus α = 1 for non-
rupturing (late stage) asexual parasites, α = 2 for rupturing asexual parasites, α = 0.364 for 
early-stage gametocytes, and α = 0.667 for late-stage gametocytes. 
Gametocytes 
It is assumed that gametocyte production begins at the onset of infection and that the 
gametocyte conversion rate (GCR) – the rate at which merozoites commit to the gametocyte 
development pathway – is log-normally distributed. A mean of the natural logarithm of GCR 
equal to −1.59, with a standard deviation of 0.13, is used based on published GCRs of 1.4% 
to 4.7% (mean of 3%) [30] and 4% [31]. There is also considerable evidence that the 
gametocyte conversion rate is elevated under stressful conditions that are unfavourable for 
parasite survival [12]. To incorporate this into the model, the GCR was allowed to rise by 2% 
on average when fever is present, following a previous model of gametocyte conversion in P. 
falciparum [27]. All gametocytes are assumed to require two days to mature before they 
became infectious to mosquitoes [32,33], and all survived for a further three days thereafter 
(with no stochastic variation) [34,35]. This longevity is considerably shorter than reported 
values for P. falciparum, however the reduced longevity of P. vivax gametocytes is offset by 
a higher rate of production [12]. 
Given the desire to develop a model that can be subsequently augmented with a between-host 
model of transmission, the predicted the number of gametocytes required to ensure at least 
one male and one female is taken up with any mosquito blood meal was also considered. The 
sex ratio of P. vivax gametocytes is difficult to ascertain in the absence of a reliable culture 
system. To predict the density of gametocytes required to ensure the carriage of at least one 
male and one female in a mosquito blood meal, a generic sex ratio for malaria is used - one 
male gametocyte is assumed to be created for every 10 female gametocytes [28]. Using a 
negative binomial distribution where the probability of finding a male gametocyte (p) is thus 
equal to 0.09, the predicted the number of gametocytes required to ensure at least one male 
and one female with 95% confidence is 31. Two assumptions are made in order to calculate 
this value: 1) a feeding mosquito will take a blood meal equivalent to 1 μL of blood [36], and 
2) the distribution of gametocytes ingested by a feeding mosquito follows a negative 
binomial distribution with constant overdispersion, where k = 3.105 [37]. 
Hypnozoites 
At the onset of infection, it is assumed that between one and four hypnozoites develop within 
the liver, each with a pre-programmed relapse date. This assumption was made on the basis 
of observations of infected hosts demonstrating recurrent relapses in the absence of 
reinfection; it is uncertain whether this repeated recurrence is due to multiple hypnozoites 
with different relapse dates developing during the initial infection, or new hypnozoites being 
created during each subsequent relapse event. Detailed data was available describing relapse 
patterns in three different regions, allowing the generation of three different relapse scenarios. 
For the purposes of this study the focus is on a Chesson style relapse pattern. Chloroquine 
studies from New Guinea and the Pacific describe a rapid pattern of relapse, with a duration 
of sequestration modelled using a combination of normal (87% - μ = 22.7, σ = 2.14) and 
binomial (13% - N = 30, p = 0.95) distributions (given a degree of bimodality in the source 
data), and providing a mean time between primary infection and first relapse, and between 
subsequent relapses, of 23.8 days [38]. This short relapse time falls within the mean time to 
relapse predicted for parasites in the wider South-East Asia region [39]. While the Chesson 
strain is largely confined to South-East Asia, this rapid pattern of relapse has resulted in the 
Chesson strain of P. vivax gaining a central role in experimental studies of the species [40]. 
It is assumed that in 40% of new infections only one hypnozoite is sequestered. A pre-
programmed relapse time is assigned by a random draw from the probability distribution 
described above and converted to a relapse date. Two, three or four hypnozoites are 
sequestered in 30%, 20% and 10% of infections, respectively; where multiple hypnozoites are 
sequestered, each is also assigned a relapse date by a random draw, multiplied by the 
hypnozoite number (e.g. a second hypnozoite, randomly assigned a relapse time of 25 days, 
will be assigned a relapse date of 25 × 2 = 50 days after the new infection is created). 
Once the relapse date is reached, 10,000 merozoites are released from the hypnozoite. These 
merozoites are treated in the same way as a new infection in the model. 
Model implementation 
The overall within-host model was implemented as a series of decision steps. Day 0 
represented the release of 10,000 merozoites in the primary infection. For each subsequent 
day of the simulation: 
1. Check to determine if fever will be triggered by the rupturing RBCs, 
2. If schizonts have matured, or hypnozoites have reached their relapse date then merozoites 
are released from within rupturing schizonts or from relapsing hypnozoites, or both: 
a. Merozoites compete to find a suitable host cell according to the preferential invasion 
module, 
b. A fraction of the merozoites commit to the gametocyte pathway, 
 
3. Any existing gametocytes age one day and gametocyte death occurs if necessary, 
4. If fever has been triggered, parasite death is simulated with a proportion of the parasite 
burden removed from the each parasite age class. 
Fitting the model 
The model was fit using digitized copies of six published time series of parasitaemia, taken 
from neurosyphilis patients treated with P. vivax infection [21]. Time series run for a 
maximum of 73 days before treatment, so the model simulation period was 80 days. Two 
variables in the model were not informed by the literature, and were instead fitted using 
available data. These variables were the strength of the clonal immunity response (β), and 
strength of the ‘killing’ power of fever (g). Gamma distributions were used to model each 
variable. After aligning the initial growth of the infection to account for the delay between 
exo-erythrocytic schizont rupture and patent parasitaemia, simulated annealing was used to fit 
the model to the mean of the six available time-series. 
The fitted model was subsequently used to simulate a set of 1,000 infections, each within a 
malaria-naïve host, which were used to determine 95% confidence intervals for model output. 
These numbers were then compared to a more comprehensive set of summary statistics 
reported for 48 sporozoite induced P. vivax infections in the same neurosyphilis study 
(henceforth referred to as the ‘McKenzie summary statistics’, or MSS) to validate the model: 
peak parasitaemia, day of peak parasitaemia, day of peak fever, peak gametocytes and day of 
peak gametocytes. Statistics recorded for trophozoite-induced infections, while available, 
were not considered, as the current model was based on a single release of merozoites from a 
single hepatic schizont, and thus more closely resembled a sporozoite-induced infection. 
A version of the fitted model was also run where chemotherapy was used to terminate 
infections. This model was included to clearly demonstrate the utility of the hypnozoite 
release component of the model. The treatment was assumed to kill all asexual parasites and 
gametocytes, and have no residual activity. 
All analyses were conducted in the R statistical computing environment [41]. 
Results 
Sample output for a single iteration of the fitted model is presented in Figure 1. The two 
parameters fit using the data were estimated as: β = Gamma(9.433, 193,134), g = 
Gamma(2.317, 160.083). Following 1,000 simulations of the fitted model, confidence 
intervals around parasitaemia were developed (Figure 2). Steps in the initial amplification of 
parasitaemia reflect the tertian nature of the infection; replication only occurs every second 
day. The typical pattern for dynamics of the parasite population generally is a rapid 
exponential increase in the first ~10 days, followed by a more gradual decline to day 80. 
Gametocyte counts follow a similar trend, but approximately two orders of magnitude lower. 
Mean days to patent parasitaemia was estimated to be six days post release of blood-stage 
parasites from the liver (95% confidence intervals 3.6-8.4 days). 
Figure 1 Example time course of a modelled infection. The infection commences with 
the release of 10,000 merozoites on Day 0. Subsequent changes in log(parasite) (solid line), 
log(gametocyte) (dotted line) and host RBC relative abundance (dashed line) are illustrated in 
the top-left panel. The lower left panel shows the ratio of parasite burden to fever threshold. 
Histograms to the right show the age profile of the host RBC population (and thus the impact 
of preferential invasion on the RBC age profile) at three points (Day 20, 40 and 60) during 
the infection. 
Figure 2 95% confidence intervals for simulated P. vivax log(parasitaemia) produced by 
the fitted model. Dotted lines represent the six digitized time series (drawn from McKenzie 
et. al. [21]) used to fit the model. 
After simulating 1,000 infections the summary statistics for comparison with the MSS were 
calculated (Table 1). Model estimates generally display similar timings of key events (peak 
parasitaemia, peak gametocytes) when compared to MSS figures. However, estimates of 
density were generally much larger than reported in MSS. 
Table 1 Comparisons between the model output and summary statistics for 48 
sporozoite-induced infections (drawn from McKenzie et. al. [21]). 
 Min Max Median Mean Std Dev
Day of 1st Parasite Peak 14 (5) 32 (34) 18 (10) 19.4 (11.4) 3.0 (5.9) 
Peak Parasitaemia (/μL) 5567 53246 14939 16475 6384 
(693) (20376) (8131) (8675) (4964) 
Day of 1st Fever 16 (3) 36 (22) 20 (8) 21.7 (NA) 3.6 (4.1) 
Peak Fever 0.447 8.336 0.983 1.134 0.574 
Day of Peak Gametocytes 16 (7.5) 38 (29.5) 20 (17) 21 (18.1) 3.8 (6.0) 
Peak Gametocytemia (/μL) 479 (20) 4939 (840) 1294 (152) 1415 (209) 548 (NA) 
Values reported by McKenzie et al. are listed in parentheses where available. Peak fever represents the 
proportion of parasites in excess of the fever threshold; no equivalent measurements were available from 
McKenzie et. al. [21]. For the model outputs, Day 0 represents the day the exo-erythrocytic schizont releases 
merozoites into the host circulation. 
The period of host infectivity can be determined by analysis of the density of gametocytes in 
the host. It is estimated that a density of 31 gametocytes/μL of host blood will ensure at least 
one male with 95% confidence. It is assumed that due to the skewed sex ratio in favour of 
females that the likelihood of a 1 μL sample containing 31 males (no females) is trivial in 
comparison to the likelihood of 31 females (no males). Given aggregation in the distribution 
of gametocytes in host blood, a density of 116.1 gametocytes/μL is required to ensure with 
95% confidence that any particular blood meal of 1 μL will contain at least 31 gametocytes, 
and thus at least one male and one female gametocyte. The model predicts that, on average, 
an infected naïve host in the absence of treatment will exhibit gametocytes densities greater 
than 116.1/μL for a mean of 34.4 days (95% CI 22, 46 days), first reaching this threshold on 
average 7.9 days post patency (95% CI 5, 10). 
Hypnozoite-mediated relapse was modelled throughout (Figure 1). However, in the absence 
of any treatment to remove the existing parasite population, the magnitude of the original 
parasite population obscures the new relapse induced infection, preventing detection of this 
second, hypnozoite-induced peak. Indeed, in some simulations, fever associated with the 
initial infection was of sufficient severity to kill the relapse parasites before they became 
established. To graphically demonstrate the relapse feature in the model, a trivial drug 
treatment module was incorporated to allow for the removal of the initial infection, and 
permit the relapsing infection to grow in the absence of this fever (Figure 3). 
Figure 3 Model demonstration of hypnozoite-mediated relapse following chemotherapy 
intervention. The initial infection is cleared by treatment on day 20 prior to relapse on day 
25. 
Discussion 
A model of the infection dynamics of P. vivax in a naïve host has been developed. This 
model is founded on a model of preferential merozoite invasion incorporating non-variant 
clonal immunity that captures the high affinity displayed by P. vivax merozoites for 
reticulocytes, and the impact this may have on limiting parasite population growth. The 
model, augmented by the inclusion of fever, the production of gametocytes, and hypnozoite-
mediated relapse, can be used to answer questions regarding the infectivity of hosts and offer 
suggestions as to the role of hypnozoite-mediated relapse in the evolution of drug resistance. 
The model presented is a simple abstraction of a true infection. The model was fit to a small 
subset of data from neurosyphillis patients as no other time-course data was readily available. 
Comparisons between model output and available data thus require some caveats. For 
example, it is unrealistic to expect a perfect match between the model and the summary data: 
it is not clear how representative the six available time-series are of the neurosyphilis dataset 
as a whole, there is no way to quantify observation error in the summary data, and timings are 
dependent on the fitting process. The similarity between model output and the summary MSS 
data does however suggest that the six available time-series do provide a reasonable 
representation of the larger data set. Thus it is not surprising that the model is unable to 
predict the full variation present in patient data. It may be that fitting to the range of values 
for the six time series, rather than simply the mean, or adding additional parameters would 
improve model fit, as would having more than six time series to use for fitting. Despite this 
shortcoming, the model does appear to provide a reasonable description of the infection 
dynamics, and can subsequently still provide some useful insights into the biology of P. 
vivax. 
The timing of the various peaks of infection are generally earlier in the MSS than in the 
model output, though in some instances (e.g. maximum day of first parasite peak, 
median/mean day of peak gametocytes) the estimates are similar. Some part of this is a 
consequence of the fitting process, but generally the cause appears to be the slow decay in the 
MSS following the peak. The model had difficulty replicating this decline, and has likely 
compensated by overshooting the peak, allowing a sharper decline to more closely match the 
MSS dataset. Thus, the model has overestimated the peak parasitaemia, in order to better fit 
the slower decline following the peak. 
It is unsurprising that estimates of density were generally much larger in the model output 
than reported in MSS; MSS statistics are a product of microscopy of patient blood, which is 
subject to the transient nature of parasite detection in peripheral blood. Factors such as 
parasite sequestration and non-synchronized rupture of parasites impact on the parasite 
density observed. These factors are not accounted for in the model, therefore it is expected 
that the model would over-estimate the measured density. 
One of the objections for preferential invasion as a mechanism for regulating parasite 
abundance is that if parasitaemia is suppressed, it follows that gametocyte abundance is also 
suppressed, reducing the probability of transmission to a new host. The model presented 
offers evidence that refutes this objection, demonstrating the possibility that preferential 
invasion can regulate parasite abundance while producing sufficient gametocytes to ensure an 
infectious host for a period of more than a month. It is further worth noting that the figures 
quoted here assume a worst case scenario of 1 male gametocyte produced for every 10 female 
gametocytes, when the generic sex ratio for malaria parasites suggest the proportion of male 
gametocytes could be as high as 1 in 5, greatly reducing the parasite density required to make 
a host infectious. 
Hypnozoite-mediated relapse provides P. vivax infections a sequestering mechanism, a 
potential sanctuary where the parasite can effectively lie dormant and await potentially more 
advantageous circumstances. At this stage it is not definitively known whether the hypnozoite 
is responsive to signals indicating a beneficial environment to re-activate an infection, or 
whether the parasite relies on chance, programming an ‘alarm clock’ to promote reactivation 
at a future time. The most notable conclusion to be drawn from the presented model is that 
hypnozoite-mediated relapse can be greatly suppressed by an existing infection and 
associated immune response. It is only when the host immune response, or treatment, 
sufficiently reduce the pre-existing infection that a hypnozoite-mediated relapse can be 
detected. Parasites from hypnozoites released prior to this time are absorbed into the existing 
parasite pool. 
Given the short time span of available patient parasitaemia simulated by the model 
(maximum of 80 days), the relapse pattern typical of the Chesson strain of vivax malaria, a 
relapse pattern that is extremely short compared to others observed, was demonstrated. If a 
longer relapse pattern, such as demonstrated in strains from East Timor [42] or Sri Lanka 
[43], were used in the model, the probability that a relapsing infection would be suppressed 
by an existing infection greatly diminishes due to the reduction in frequency of fever 
throughout an infection. This raises an interesting question: if hypnozoites evolved in 
response to environmental conditions where the presence of the mosquito vector is 
intermittent, what is the purpose of a short relapse pattern such as exhibited by the Chesson 
strain? The original infection is likely to still be active, and mosquito abundance is unlikely to 
significantly change in such a short time period. This interesting evolutionary question 
warrants further consideration. 
Conclusions 
In the absence of an ex vitro culture system for P. vivax, modelling provides a useful tool for 
exploring aspects of the biology and ecology of the parasite. Here a model of the dynamics of 
an infection within a host is presented and used to address questions about host infectivity, 
the role of preferential invasion in suppressing gametocyte production, and hypnozoite-
mediated relapse. While such a model is ultimately an abstraction of a real infection, useful 
insights can be drawn from the outputs. Future work will allow the development of 
community-scale, multiple-host models, where parasite infections can be transmitted between 
hosts by mosquito vectors; such models will facilitate investigations into the suitability and 
effectiveness of interventions to control disease outbreaks and elimination/eradication 
strategies for P. vivax. 
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